ATLANTA -- A study by researchers at Mayo Clinic's campus in Jacksonville, Florida has found that barriers to patients receiving stem cell therapy as part of their treatment for multiple myeloma include income, education, insurance status and access to care at an academic center or facility that treats a high volume of patients.
Combining a 16-week initial course of the medication omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, new clinical trial findings show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.
Continence problems are among the most common paediatric health problems. It's commonly believed that continence problems resolve with age in all children. However, severe incontinence in childhood can persist into adolescence. New research has found teenagers with incontinence are at greater risk of underachieving academically, and need more support to remove barriers so they can reach their academic potential.
The prevalence of urinary incontinence in teens is around three to four per cent and around one per cent suffer from bowel incontinence.
Looking to bolster the body's immune system in the fight against infection and cancer, researchers at the University of California San Diego and their colleagues have identified a promising new strategy to program the immune system to meet the pathogen or malignancy in the tissues where they first pose a threat.
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation therapy.
Glioblastoma is the most common and aggressive type of brain tumor, with a particularly poor prognosis. Patients are treated with surgery, radiation therapy and chemotherapy, but there is no cure.
Boston, MA -- This report is part of a series titled "Discrimination in America." The series is based on a survey conducted for National Public Radio, the Robert Wood Johnson Foundation, and Harvard T.H. Chan School of Public Health. While many surveys have explored Americans' beliefs about discrimination, this survey asks people about their own personal experiences with discrimination.
A survey of patients admitted to Massachusetts General Hospital (MGH) has found that patients reporting greater levels of satisfaction with their care and good communication with the health care providers were significantly less like to readmitted to the hospital in the 30 days after discharge. The study, the first to focus on patients' perceptions on future readmission during their initial hospitalization, has been published in BMJ Quality & Safety.
Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells' chromatin. The study, which will be published December 11 in the Journal of Cell Biology, suggests that targeting this enzyme could make pancreatic cancer cells more vulnerable to existing therapies that currently have only limited effect against this deadly form of cancer.
A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according to researchers at the Stanford University School of Medicine and the University of Michigan.
ATLANTA - University of North Carolina Lineberger Comprehensive Cancer Center researchers report that pairing an immunotherapy drug with chemotherapy proved beneficial for some patients with acute myeloid leukemia whose disease did not respond to standard treatment or had relapsed.